Abstract 162P
Background
To evaluate clinical usefulness of hypofractionated radiotherapy (HRT) for pulmonary metastases from hepatocellular carcinoma (HCC) and investigate the prognostic factors affecting treatment outcome.
Methods
From March 2006 to May 2018, 58 patients with less than five pulmonary metastases from HCC who underwent HRT were analyzed retrospectively. Primary endpoint was treatment response rate. Secondary endpoints were progression-free survival, overall survival, prognostic factors affecting treatment outcomes and treatment-related side effects.
Results
The treatment response (complete and partial response) rate was 77.6 %, and the maximum treatment response was presented between 1 to 3 months after completion of HRT. The local control rate was 63.8 %. The median survival time was 16.3 months for all patients. The 1-year and 3-year overall survival rates were 79.3 % and 37.9 %, respectively. The median progression-free survival time was about 5 months and eighty-six percent of the patients (n = 50) showed post-treatment disease progression. Multivariate analysis identified the common prognostic factors for both OS and PFS as the planning target volume and maximal treatment response after HRT. The progression-free survival period was also a prognostic factor for OS in multivariate analysis. The grade 3 and 4 severe toxicities were reported in 4 and 3 patients, respectively.Table:
162P Prognostic factors
OS | PFS | |||||
---|---|---|---|---|---|---|
Median±SD* | p value† | Median±SD* | p value† | |||
Variable | (mo) | UVA | MVA | (mo) | UVA | MVA |
Age | 0.650 | 0.030 | 0.012 | |||
< 60 | 16.2±4.6 | 3.7±3.7 | ||||
≥ 60 | 21.4±7.9 | 4.9±1.3 | ||||
ECOG | 0.097 | 0.401 | ||||
0 | 44.3±17.2 | 8.0±3.0 | ||||
1, 2 | 16.3±4.5 | 3.7±1.3 | ||||
PTV size | 0.017 | 0.003 | 0.027 | 0.003 | ||
< 19 cc | 30.3±8.5 | 5.7±2.0 | ||||
≥ 19 cc | 11.5±2.1 | 3.0±0.3 | ||||
Type I max response | 0.013 | 0.000 | 0.029 | |||
CR+PR | 20.1±4.3 | 5.1±1.6 | ||||
SD+PD | 6.0±1.2 | 1.3±1.1 | ||||
Type II max response | 0.006 | 0.014 | 0.018 | |||
CR+PR+SD | 20.1±3.5 | 5.1±1.3 | ||||
PD | 4.6±1.8 | 1.2±0.1 | ||||
PFS period | 0.001 | 0.003 | ||||
< 5 mon | 10.6±3.5 | |||||
≥ 5 mon | 44.3±11.7 | |||||
Overall | 16.3±4.4 | 4.9±1.2 |
Conclusions
The considerable treatment outcome and acceptable toxicity may indicate clinical usefulness of HRT for patients who have less than five pulmonary metastases from HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract